| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA466: Baricitinib for moderate to severe rheumatoid arthritis |
|
Medicine details |
|
| Medicine name | baricitinib (Olumiant®) |
| Formulation | 2 mg, 4 mg film-coated tablet |
| Reference number | 953 |
| Indication | As monotherapy or in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease‑modifying anti‑rheumatic drugs |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2017 |
| NICE guidance | TA466: Baricitinib for moderate to severe rheumatoid arthritis |